The TFIID complex is a new autoantibody target in systemic sclerosis

Jean-Baptiste Vulsteke; Birthe Michiels; Vanessa Smith; Yves Piette; Marie Vanthuyne; Carole Lacout; Antoine Brochard; Mohammed Tikly; Jonas De Leeuw; Doreen Dillaerts; Tom Dehaemers; Petra De Haes; Jan L Lenaerts; Daniel Blockmans; Neil McHugh; Sarah Tansley; Emeline Vinatier; Frédéric Houssiau; Carolien Bonroy; Ellen De Langhe; Xavier Bossuyt

doi:10.1016/j.ard.2025.05.008

The TFIID complex is a new autoantibody target in systemic sclerosis

Jean-Baptiste Vulsteke, Birthe Michiels, Vanessa Smith, Yves Piette, Marie Vanthuyne, Carole Lacout, Antoine Brochard, Mohammed Tikly, Jonas De Leeuw, Doreen Dillaerts, Tom Dehaemers, Petra De Haes, Jan L Lenaerts, Daniel Blockmans, Neil McHugh, Sarah Tansley, Emeline Vinatier, Frédéric Houssiau, Carolien Bonroy, Ellen De LangheXavier Bossuyt

Research output: Contribution to journal › Article › peer-review

9 Downloads (Pure)

Abstract

Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

Original language	English
Journal	Annals of the Rheumatic Diseases
Early online date	19 Jun 2025
DOIs	https://doi.org/10.1016/j.ard.2025.05.008
Publication status	E-pub ahead of print - 19 Jun 2025

Acknowledgements

We thank An Knoops for performing the indirect immunofluorescence assay.

Funding

JB Vulsteke held a Research Foundation—Flanders (FWO) SB Fellowship (1S62419N). This study was supported by the Research Fund KU Leuven (C3/20/042) and by FWO-Applied Biomedical research (TBM) (T004821N).

Access to Document

10.1016/j.ard.2025.05.008

TFIID_Letter_with_revisions_finalAccepted author manuscript, 302 KBLicence: CC BY

Cite this

Vulsteke, J.-B., Michiels, B., Smith, V., Piette, Y., Vanthuyne, M., Lacout, C., Brochard, A., Tikly, M., De Leeuw, J., Dillaerts, D., Dehaemers, T., De Haes, P., Lenaerts, J. L., Blockmans, D., McHugh, N., Tansley, S., Vinatier, E., Houssiau, F., Bonroy, C., ... Bossuyt, X. (2025). The TFIID complex is a new autoantibody target in systemic sclerosis. Annals of the Rheumatic Diseases. Advance online publication. https://doi.org/10.1016/j.ard.2025.05.008

Vulsteke, J-B, Michiels, B, Smith, V, Piette, Y, Vanthuyne, M, Lacout, C, Brochard, A, Tikly, M, De Leeuw, J, Dillaerts, D, Dehaemers, T, De Haes, P, Lenaerts, JL, Blockmans, D, McHugh, N , Tansley, S, Vinatier, E, Houssiau, F, Bonroy, C, De Langhe, E & Bossuyt, X 2025, 'The TFIID complex is a new autoantibody target in systemic sclerosis', Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.05.008

@article{f52786f22bfd4969904b2c796a16f035,

title = "The TFIID complex is a new autoantibody target in systemic sclerosis",

abstract = "Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.",

author = "Jean-Baptiste Vulsteke and Birthe Michiels and Vanessa Smith and Yves Piette and Marie Vanthuyne and Carole Lacout and Antoine Brochard and Mohammed Tikly and {De Leeuw}, Jonas and Doreen Dillaerts and Tom Dehaemers and {De Haes}, Petra and Lenaerts, {Jan L} and Daniel Blockmans and Neil McHugh and Sarah Tansley and Emeline Vinatier and Fr{\'e}d{\'e}ric Houssiau and Carolien Bonroy and {De Langhe}, Ellen and Xavier Bossuyt",

year = "2025",

month = jun,

day = "19",

doi = "10.1016/j.ard.2025.05.008",

language = "English",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The TFIID complex is a new autoantibody target in systemic sclerosis

AU - Vulsteke, Jean-Baptiste

AU - Michiels, Birthe

AU - Smith, Vanessa

AU - Piette, Yves

AU - Vanthuyne, Marie

AU - Lacout, Carole

AU - Brochard, Antoine

AU - Tikly, Mohammed

AU - De Leeuw, Jonas

AU - Dillaerts, Doreen

AU - Dehaemers, Tom

AU - De Haes, Petra

AU - Lenaerts, Jan L

AU - Blockmans, Daniel

AU - McHugh, Neil

AU - Tansley, Sarah

AU - Vinatier, Emeline

AU - Houssiau, Frédéric

AU - Bonroy, Carolien

AU - De Langhe, Ellen

AU - Bossuyt, Xavier

PY - 2025/6/19

Y1 - 2025/6/19

N2 - Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

AB - Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

U2 - 10.1016/j.ard.2025.05.008

DO - 10.1016/j.ard.2025.05.008

M3 - Article

C2 - 40541453

SN - 0003-4967

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -

The TFIID complex is a new autoantibody target in systemic sclerosis

Abstract

Acknowledgements

Funding

Access to Document

Fingerprint

Cite this